Atrial fibrillation and atrial fibrosis

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 6, 2011, Pages 625-629

  Tan, Alex Y ^a   Zimetbaum, Peter ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

atrial fibrillation; fibrosis

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 85028118511     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182073c78     Document Type: Review

References (70)

1. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet. 2006;367: 262-272. (Pubitemid 43107672)
2. Beyerbach DM, Zipes DP. Mortality as an endpoint in atrial fibrillation. Heart Rhythm. 2004;1:8-18.
3. Jäs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118:2498-2505.
4. Terasawa T, Balk EM, Chung M, et al. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med. 2009;151:191-202.
5. Willems S, Klemm H, Rostock T, et al. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. Eur Heart J. 2006;27:2871-2878. (Pubitemid 44871470)
6. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54:230-246. (Pubitemid 34327903)
7. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802-809. (Pubitemid 351260071)
8. Anyukhovsky EP, Sosunov EA, Plotnikov A, et al. Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res. 2002;54:462-469. (Pubitemid 34327925)
9. Ohtani K, Yutani C, Nagata S, et al. High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol. 1995;25: 1162-1169.
10. Bailey GW, Braniff BA, Hancock EW, et al. Relation of left atrial pathology to atrial fibrillation in mitral valvular disease. Ann Intern Med. 1968;69:13-20.
11. Sinno H, Derakhchan K, Libersan D, et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003;107:1930-1936. (Pubitemid 36444137)
12. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002;54:361-379. (Pubitemid 34327915)
13. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999; 100:87-95. (Pubitemid 29297945)
14. Levy S. Factors predisposing to the development of atrial fibrillation. Pacing Clin Electrophysiol. 1997;20:2670-2674.
15. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96: 1180-1184. (Pubitemid 27344221)
16. Boldt A,Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90:400-405. (Pubitemid 38406914)
17. Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004;109:363-368. (Pubitemid 38133905)
18. Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009; 119:1758-1767.
19. Mahnkopf C, Badger TJ, Burgon NS, et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm. 2010 Jul 2 [Epub ahead of print].
20. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
21. Everett TH, Wilson EE, Verheule S, et al. Structural atrial remodeling alters the substrate and spatiotemporal organization of AF: a comparison in canine models of structural and electrical atrial remodeling. Am J Physiol Heart Circ Physiol. 2006;291:H2911-H2923. (Pubitemid 44904093)
22. Everett TH 4th, Verheule S, Wilson EE, et al. Left atrial dilatation resulting from chronic mitral regurgitation decreases spatiotemporal organization of atrial fibrillation in left atrium. Am J Physiol Heart Circ Physiol. 2004;286:H2452-2460. (Pubitemid 38685264)
23. Anyukhovsky EP, Sosunov EA, Plotnikov A, et al. Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res. 2002;54:462-469. (Pubitemid 34327925)
24. Li D, Melnyk P, Feng J, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101:2631-2638. (Pubitemid 30350643)
25. Yeh YH, Wakili R, Qi X, et al. A unique calcium handling phenotype underlies arrhythmogenesis and contractile dysfunction in failing canine atrium. Heart Rhythm. 2007;4:S156.
26. Fenelon G, Shepard RK, Stambler BS. Focal origin of atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol. 2003;14:1093-1102. (Pubitemid 37412088)
27. Okuyama Y, Miyauchi Y, Park AM, et al. High resolution mapping of the pulmonary vein and the vein of Marshall during induced atrial fibrillation and atrial tachycardia in a canine model of pacing-induced congestive heart failure. J Am Coll Cardiol. 2003;42:348-360. (Pubitemid 36851429)
28. Stambler BS, Fenelon G, Shepard RK, et al. Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol. 2003;14:499-507. (Pubitemid 36583911)
29. Aharinejad S, Krenn K, Paulus P, et al. Differential role of TGF-beta1/ bFGF and ET-1 in graft fibrosis in heart failure patients. Am J Transplant. 2005;5:2185-2192. (Pubitemid 41648465)
30. Weber KT, Brilla CG, Campbell SE, et al. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993;88(Suppl 1):107-124. (Pubitemid 23226442)
31. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. (Pubitemid 40523144)
32. Xiao HD, Fuchs S, Campbell DJ, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol. 2004;165:1019-1032. (Pubitemid 39129307)
33. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608-2614. (Pubitemid 33104801)
34. Sugden PH, Clerk A. Stress-responsive mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83:345-352. (Pubitemid 28389964)
35. Inoue N, Ohkusa T, Nao T, et al. Rapid electrical stimulation of contraction modulates gap junction protein in neonatal rat cultured cardiomyocytes: involvement of mitogen-activated protein kinases and effects of angiotensin II-receptor antagonist. J Am Coll Cardiol. 2004;44:914-922. (Pubitemid 39099593)
36. Schultz JJ, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787-796. (Pubitemid 34263155)
37. Lee AA, Dillmann WH, McCulloch AD, et al. Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol. 1995;27:2347-2357.
38. Everett AD, Tufro-McReddie A, Fisher A, et al. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension. 1994;23:587-592.
39. Hao J, Wang B, Jones SC, et al. Interaction between angiotensin II and SMAD proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol. 2000;279:H3020-H3030. (Pubitemid 32005893)
40. Hanna N, Cardin S, Leung TK, et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res. 2004;63:236-244. (Pubitemid 38900838)
41. Nakajima H, Nakajima HO, Salcher O, et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res. 2000;86:571-579. (Pubitemid 30165049)
42. Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res. 2004;94:1458-1465. (Pubitemid 38780318)
43. Burstein B, Libby E, Calderone A, et al. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation. 2008;117: 1630-1641. (Pubitemid 351482606)
44. Hinescu ME, Gherghiceanu M, Mandache E, et al. Interstitial Cajal-like cells (ICLC) in atrial myocardium: ultrastructural and immunohistochemical characterization. J Cell Mol Med. 2006;10:243-257. (Pubitemid 44874307)
45. Liao CH, Akazawa H, Tamagawa M, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest. 2010;120:242-253.
46. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol. 1999;277:C1-C9.
47. Camelliti P, Green CR, LeGrice I, et al. Fibroblast network in rabbit sinoatrial node: structural and functional identification of homogeneous and heterogeneous cell coupling. Circ Res. 2004;94:828-835. (Pubitemid 38451745)
48. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-2891. (Pubitemid 33139098)
49. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104: 174-180. (Pubitemid 32655834)
50. Chen CL, Huang SK, Lin JL, et al. Upregulation of matrix metalloproteinase- 9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol. 2008;45:742-753.
51. Rudolph V, Andrié RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;16:470-474.
52. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010;375:1212-1223.
53. Boldt A, Scholl A, Garbade J, et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol. 2006;101:261-267.
54. Hirayama Y, Atarashi H, Kobayashi Y, et al. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J. 2005;69:671-676. (Pubitemid 40812368)
55. L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004;44:159-164. (Pubitemid 38976480)
56. Murray KT, Rottman JN, Arbogast PG, et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004;1:669-675. (Pubitemid 40028772)
57. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107:2926-2931. (Pubitemid 36736634)
58. Zaman AG, Kearney MT, Schecter C, et al. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J. 2004;147:823-827. (Pubitemid 38880988)
59. GISSI-AF Investigators; Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360: 1606-1617.
60. Dixen U, Ravn L, Soeby-Rasmussen C, et al. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology. 2007;108:35-39. (Pubitemid 47014348)
61. Milliez P, Deangelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005;26:2193-2199. (Pubitemid 41408006)
62. Shroff SC, Ryu K, Martovitz NL, et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:534-541.
63. Lee KW, Everett TH 4th, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006;114:1703-1712. (Pubitemid 44607118)
64. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, et al. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res. 2006;69:865-875. (Pubitemid 43227985)
65. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004;25:1100-1107. (Pubitemid 38842447)
66. Shiroshita-Takeshita A, Schram G, Lavoie J, et al. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110: 2313-2319. (Pubitemid 39407332)
67. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007;74:75-84. (Pubitemid 46366949)
68. Adam O, Neuberger HR, Bohm M, et al. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation. 2008;118:1285-1293.
69. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5: 30-41.
70. Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007;116:2101-2109. (Pubitemid 350060347)